Free Trial
NASDAQ:NEPH

Nephros (NEPH) Stock Price, News & Analysis

Nephros logo
$3.47 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$3.54 +0.06 (+1.87%)
As of 05/22/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Nephros Stock (NASDAQ:NEPH)

Advanced

Key Stats

Today's Range
$3.43
$3.69
50-Day Range
$2.78
$3.69
52-Week Range
$2.28
$6.42
Volume
41,916 shs
Average Volume
35,103 shs
Market Capitalization
$37.68 million
P/E Ratio
49.58
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Moderate Buy

Company Overview

Nephros Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

NEPH MarketRank™: 

Nephros scored higher than 52% of companies evaluated by MarketBeat, and ranked 466th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nephros has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

  • Upside Potential

    Nephros has a consensus price target of $6.00, representing about 72.9% upside from its current price of $3.47.

  • Amount of Analyst Coverage

    Nephros has only been the subject of 1 research reports in the past 90 days.

  • Read more about Nephros' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nephros is 49.58, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.78.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nephros is 49.58, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.21.

  • Price to Book Value per Share Ratio

    Nephros has a P/B Ratio of 3.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Nephros' valuation and earnings.
  • Percentage of Shares Shorted

    0.29% of the float of Nephros has been sold short.
  • Short Interest Ratio / Days to Cover

    Nephros has a short interest ratio ("days to cover") of 1.24, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nephros has recently decreased by 28.15%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Nephros does not currently pay a dividend.

  • Dividend Growth

    Nephros does not have a long track record of dividend growth.

    • Insider Buying vs. Insider Selling

      In the past three months, Nephros insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      6.70% of the stock of Nephros is held by insiders.

    • Percentage Held by Institutions

      41.10% of the stock of Nephros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Nephros' insider trading history.
    Receive NEPH Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter.

    SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    NEPH Stock News Headlines

    Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
    After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall of Fame Trader Jon Najarian now says EVERYONE is missing an even bigger story about the SpaceX IPO… That it's just the start of an Elon Musk $44 trillion "Superconvergence…" An event that could kick off as soon as June 12th.tc pixel
    Nephros, Inc. Q1 2026 Earnings Call Summary
    See More Headlines

    NEPH Stock Analysis - Frequently Asked Questions

    Nephros' stock was trading at $4.88 at the beginning of 2026. Since then, NEPH shares have decreased by 28.9% and is now trading at $3.47.

    Nephros Inc. (NASDAQ:NEPH) announced its earnings results on Thursday, May, 7th. The company reported $0.01 earnings per share for the quarter, meeting analysts' consensus estimates of $0.01. The firm had revenue of $5.21 million for the quarter, compared to the consensus estimate of $5.02 million. Nephros had a trailing twelve-month return on equity of 7.66% and a net margin of 4.06%.
    Read the conference call transcript
    .

    Top institutional investors of Nephros include Renaissance Technologies LLC (0.92%) and Dimensional Fund Advisors LP (0.19%). Insiders that own company stock include Arthur H Amron and Robert R Jr Banks.
    View institutional ownership trends
    .

    Shares of NEPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Nephros investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Jabil (JBL), Arista Networks (ANET), Disc Medicine (IRON) and Novo Nordisk A/S (NVO).

    Company Calendar

    Last Earnings
    5/07/2026
    Today
    5/25/2026
    Next Earnings (Estimated)
    8/06/2026
    Fiscal Year End
    12/31/2026

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED PRODUCTS
    Sub-Industry
    Medical Equipment
    Current Symbol
    NASDAQ:NEPH
    CIK
    1196298
    Employees
    30
    Year Founded
    1997

    Price Target and Rating

    High Price Target
    $6.00
    Low Price Target
    $6.00
    Potential Upside/Downside
    +72.9%
    Consensus Rating
    Moderate Buy
    Rating Score (0-4)
    2.50
    Research Coverage
    2 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    $0.07
    Trailing P/E Ratio
    49.58
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    $1.19 million
    Net Margins
    4.06%
    Pretax Margin
    4.12%
    Return on Equity
    7.66%
    Return on Assets
    5.86%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    4.55
    Quick Ratio
    3.12

    Sales & Book Value

    Annual Sales
    $18.79 million
    Price / Sales
    2.01
    Cash Flow
    $0.13 per share
    Price / Cash Flow
    27.66
    Book Value
    $0.99 per share
    Price / Book
    3.51

    Miscellaneous

    Outstanding Shares
    10,860,000
    Free Float
    10,130,000
    Market Cap
    $37.68 million
    Optionable
    Not Optionable
    Beta
    1.47

    Social Links

    7 Energy Stocks to Buy and Hold Forever Cover

    With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

    Get This Free Report

    This page (NASDAQ:NEPH) was last updated on 5/26/2026 by MarketBeat.com Staff.
    From Our Partners